Doceree, Healthcare Marketing’s AI-Powered Operating System, Earns Frost & Sullivan’s 2026 Global Technology Innovation Leadership Recognition
Doceree is recognized as the AI leader in healthcare marketing for unifying the full prescription journey — from physician awareness to fill — on a single, clinically intelligent operating system. SAN ANTONIO, May 26, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Doceree has been awarded the 2026 Global Technology Innovation Leadership Recognition in the AI-powered...
Neurophet Launches Joint Study with VHIR on ‘Neurophet AQUA MS’, Accelerating AI Algorithm Validation
Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis...
ODYSS Launches Global Co-Creator Program, Defining the Future of AI-Powered Dietary Management
SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- ODYSS, a pioneer in AI-driven dietary management, announced today that it had launched its Co-Creator Program for early users of its flagship product, N1, on May 25. This milestone marks the transition of the world's first AI Dietary Wearable from experimental prototypes to real-world use, bringing effortless, automated dietary management to everyday...
Beyond the Millimeter: NaoTrac Redefines Precision Standards via Intelligent Surgical Navigation
ZHUBEI, May 26, 2026 /PRNewswire/ -- Precision and minimally invasive are more than technical goals—they are a pledge to uphold patient dignity. In the high-stakes realm of neurosurgery, where the brain's complexity leaves only a millimeter of room for error, the demand for perfection is redefining the future of medical innovation. Prof. Dr. med....
Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
HkeyBio Builds a High-Efficiency Wet-Lab Validation Engine with Comprehensive CRO Service Upgrades in 2026 BOSTON and SUZHOU, China, May 26, 2026 /PRNewswire/ -- I. Industry Background: AI-Driven Drug Discovery Fuels Explosive Demand for Wet-Lab Validation, Creating New Opportunities for Specialized Autoimmune CROs The global population affected by autoimmune diseases continues to grow steadily, driving strong demand for innovative therapeutics...
SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia’s VECOL to Advance Local Vaccine Manufacturing in Latin America
SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative through technology transfer and local manufacturing cooperation with state-owned pharmaceutical company VECOL This alliance enables SK bioscience to enter Latin America by manufacturing SKYVaricella, with potential expansion into a broader vaccine portfolio. SK–VECOL partnership establishes strategic foothold for broader LATAM...
Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026
Earnings Call Scheduled for 9:30 p.m. ET on June 8, 2026 MILPITAS, Calif., May 26, 2026 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its first quarter 2026 unaudited financial results on Monday, June 8, 2026. Management will hold...
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing Phase 1b clinical trial evaluating lead asset...
HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to...
Venus Medtech Hosts Inaugural Global Partner Summit in Paris
Company highlights international growth strategy, expanding structural heart portfolio, and commercialization priorities PARIS, May 26, 2026 /PRNewswire/ -- Venus Medtech convened its inaugural Global Partner Summit in Paris under the theme "Insights, Innovation, Impact," bringing together distributors and commercial partners to discuss the company's international growth strategy, structural heart portfolio expansion, and long-term commercialization priorities. The event marked a...
